[1] Ychou M,Boige V,Pignon JP,et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma:an FNCLCC and FFCD multicenter phase Ⅲ trial[J].J Clin Oncol,2011,29(13):1715-1721.DOI:10.1200/JCO.2010.33.0597.
[2] Kelsen DP,Ginsberg R,Pajak TF,et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer[J].N Engl J Med,1998,339(27):1979-1984.
[3] Kelsen DP,Winter KA,Gunderson LL,et al. Long-term results of RTOG trial 8911(USA Intergroup 113):a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer[J].J Clin Oncol,2007,25(24):3719-3725.
[4] Schuhmacher C,Gretschel S,Lordick F,et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia:European Organisation for Research and Treatment of Cancer randomized trial 40954[J].J Clin Oncol,2010,28(35):5210-5218.DOI:10.1200/JCO.2009.26.6114.
[5] Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer:a randomised controlled trial[J].Lancet,2002,359(9319):1727-1733.
[6] Allum WH,Stenning SP,Bancewicz J,et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer[J].J Clin Oncol,2009,27(30):5062-5067.DOI:10.1200/JCO.2009.22.2083.
[7] Ronellenfitsch U, Schwarzbach M, Hofheinz R, et al. Preoperative chemo (radio) therapy versus primary surgery for gastroesophageal adenocarcinoma:systematic review with meta-analysis combining individual patient and aggregate data[J].Eur J Cancer,2013,49(15):3149-3158.DOI:10.1016/j.ejca.2013.05.029.
[8] Webb A,Cunningham D,Scarffe JH,et al. Randomized trial comparing epirubicin,cisplatin,and fluorouracil versus fluorouracil,doxorubicin,and methotrexate in advanced esophagogastric cancer[J].J Clin Oncol,1997, 15(1):261-267.
[9] Ross P,Nicolson M,Cunningham D,et al. Prospective randomized trial comparing mitomycin,cisplatin,and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin,cisplatin,and PVI 5-FU in advanced esophagogastric cancer[J].J Clin Oncol,2002, 20(8):1996-2004.
[10] Cunningham D,Allum WH,Stenning SP,et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer[J].N Engl J Med,2006,355(1):11-20.
[11] Ando N,Iizuka T,Ide H,et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus:a Japan Clinical Oncology Group Study—JCOG9204[J].J Clin Oncol,2003,21(24):4592-4596.
[12] Ando N,Kato H,Igaki H,A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907)[J].Ann Surg Oncol,2012,19(1):68-74.DOI:10.1245/s10434-011-2049-9.
[13] Zheng Y,Li Y,Liu X,et al. Reevaluation of neoadjuvant chemotherapy for esophageal squamous cell carcinoma:a meta-analysis of randomized controlled trials over the past 20 years[J].Medicine (Baltimore),2015,94(27):e1102.DOI:10.1097/MD.0000000000001102.
[14] Pasquali S,Yim G,Vohra RS,et al. Survival after neoadjuvant and adjuvant treatments compared to surgery alone for resectable esophageal carcinoma:a network meta-analysis[J].Ann Surg,2017,265(3):481-491.DOI:10.1097/SLA.0000000000001905.
[15] Sjoquist KM,Burmeister BH,Smithers BM,et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma:an updated meta-analysis[J].Lancet Oncol,2011,12(7):681-692.DOI:10.1016/S1470-2045(11)70142-5.
[16] Baba M,Natsugoe S,Shimada M,et al. Prospective evaluation of preoperative chemotherapy in resectable squamous cell carcinoma of the thoracic esophagus[J].Dis Esophagus,2000,13(2):136-141.
[17] Hara H,Tahara M,Daiko H,et al. Phase Ⅱ feasibility study of preoperative chemotherapy with docetaxel,cisplatin,and fluorouracil for esophageal squamous cell carcinoma[J].Cancer Sci,2013,104(11):1455-1460.DOI:10.1111/cas.12274.
[18] Ui T,Fujii H,Hosoya Y,et al. Comparison of preoperative chemotherapy using docetaxel,cisplatin and fluorouracil with cisplatin and fluorouracil in patients with advanced carcinoma of the thoracic esophagus[J].Dis Esophagus,2015,28(2):180-187.DOI:10.1111/dote.12187.
[19] Shiraishi O,Yamasaki M,Makino T,et al. Feasibility of preoperative chemotherapy with docetaxel,cisplatin,and 5-fluorouracil versus adriamycin,cisplatin,and 5-fluorouracil for resectable advanced esophageal cancer[J].Oncology,2017,92(2):101-108.DOI:10.1159/000452765.
[20] Yamasaki M,Yasuda T,Yano M,et al. Multicenter randomized phase Ⅱ study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003)[J].Ann Oncol,2017,28(1):116-120.DOI:10.1093/annonc/mdw439.
[21] Nomura M,Oze I,Abe T,et al. Impact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage Ⅲ or T3 esophageal cancer:a propensity score-matched analysis[J].Cancer Chemother Pharmacol,2015,76(2):357-363.DOI:10.1007/s00280-015-2806-8.
[22] Watanabe M,Baba Y,Yoshida N,et al. Outcomes of preoperative chemotherapy with docetaxel,cisplatin,and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer[J].Ann Surg Oncol,2014,21(9):2838-2844.DOI:10.1245/s10434-014-3684-8.
[23] Huang TC,Hsu CH,Lin CC,et al. Systematic review and network meta-analysis:neoadjuvant chemoradiotherapy for locoregional esophageal cancer[J].Jpn J Clin Oncol,2015,45(11):1023-1028.DOI:10.1093/jjco/hyv119.
[24] van Hagen P,Hulshof MC,van Lanschot JJ.Preoperative chemoradiotherapy for esophageal or junctional cancer[J].N Engl J Med,2012,366(22):2074-2084.DOI:10.1056/NEJMoa1112088.
[25] Shapiro J,van Lanschot JJB,Hulshof MCCM,et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS):long-term results of a randomised controlled trial[J].Lancet Oncol,2015,16(9):1090-1098.DOI:10.1016/S1470-2045(15)00040-6.
[26] Nygaard K,Hagen S,Hansen HS,et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma:a randomized,multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer[J].World J Surg,1992,16(6):1104-1109;discussion 1110.
[27] Le Prise E,Etienne PL,Meunier B,et al. A randomized study of chemotherapy,radiation therapy,and surgery versus surgery for localized squamous cell carcinoma of the esophagus[J].Cancer,1994,73(7):1779-1784.
[28] Bosset JF,Gignoux M,Triboulet JP,et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus[J].N Engl J Med,1997,337(3):161-167.
[29] Lee JL,Park SI,Kim SB,et al. A single institutional phase Ⅲ trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgeryalone for resectable esophageal squamous cell carcinoma[J].Ann Oncol,2004,15(6):947-954.
[30] Urba SG,Orringer MB,Turrisi A,et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma[J].J Clin Oncol,2001,19(2):305-313.
[31] Burmeister BH,Smithers BM,Gebski V,et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus:a randomised controlled phase Ⅲ trial[J].Lancet Oncol,2005,6(9):659-668.
[32] Fowler JF,Lindstrom MJ.Loss of local control with prolongation in radiotherapy[J].Int J Radiat Oncol Biol Phys,1992,23(2):457-467.
[33] Yang H,Fu JH,Liu MZ,et al. A phase Ⅲ clinical trial of neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010)[J].Chin J of Med,2012,92(15):1028-1032.
[34] Walsh TN,Noonan N,Hollywood D,et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma[J].N Engl J Med,1996,335(7):462-467.
[35] Tepper J,Krasna MJ,Niedzwiecki D,et al. Phase Ⅲ trial of trimodality therapy with cisplatin,fluorouracil,radiotherapy,and surgery compared with surgery alone for esophageal cancer:CALGB 9781[J].J Clin Oncol,2008,26(7):1086-1092.DOI:10.1200/JCO.2007.12.9593.
[36] Mariette C,Dahan L,Mornex F,et al. Surgery alone versus chemoradiotherapy followed by surgery for stage Ⅰ and Ⅱ esophageal cancer:final analysis of randomized controlled phase Ⅲ trial FFCD 9901[J].J Clin Oncol,2014,32(23):2416-2422.DOI:10.1200/JCO.2013.53.6532.
[37] Speicher PJ,Ganapathi AM,Englum BR,et al. Induction therapy does not improve survival for clinical stage T2N0 esophageal cancer[J].J Thorac Oncol,2014,9(8):1195-1201.DOI:10.1097/JTO.0000000000000228.
[38] FC Mota, I.Cecconellob, F.R.Takedac,et al. Neoadjuvant therapy or upfront surgery? A systematic review and metaanalysis of T2N0 esophageal cancer treatment options[J].Int J Sur,2018,54(Pt A):176-181.
[39] Chao YK,Ku HY,Chen CY,et al. Induction therapy before surgery improves survival in patients with clinical T3N0 esophageal cancer:a nationwide study in Taiwan[J].Dis Esophagus.2017,30(12):1-7.DOI:10.1093/dote/dox103.
[40] Mantziari S,Gronnier C,Renaud F,et al. Survival benefit of neoadjuvant treatment in clinical t3n0m0 esophageal cancer:results from a retrospective multicenter European study[J].Ann Surg,2017,266(5):805-813.DOI:10.1097/SLA.0000000000002402.
[41] Stiles BM,Mirza F,Coppolino A,et al. Clinical T2-3N0M0 esophageal cancer:the risk of node positive disease[J].Ann Thorac Surg,2011,92(2):491-496;discussion 496-8.DOI:10.1016/j.athoracsur.2011.04.004.
[42] H lscher AH,Bollschweiler E,Bogoevski D.Prognostic impact of neoadjuvant chemoradiation in cT3 oesophageal cancer-A propensity score matched analysis[J].Eur J Cancer,2014,50(17):2950-2957.DOI:10.1016/j.ejca.2014.08.020.
[43] de Heer EC,Hulshoff JB,Klerk D.Effect of extending the original eligibility criteria for the CROSS neoadjuvant chemoradiotherapy on toxicity and survival in esophageal cancer[J].Ann Surg Oncol,2017,24(7):1811-1820.DOI:10.1245/s10434-017-5797-3.
[44] Kumagai K,Rouvelas I,Tsai JA,et al. Survival benefit and additional value of preoperative chemoradiotherapy in resectable gastric and gastro-oesophageal junction cancer:a direct and adjusted indirect comparison meta-analysis[J].Eur J Surg Oncol,2015,41(3):282-294.DOI:10.1016/j.ejso.2014.11.039.
[45] Morgan MA,Lewis WG,Hopper AN,et al. Prospective comparison of transthoracic versus transhiatal esophagectomy following neoadjuvant therapy for esophageal cancer[J].Dis Esophagus,2007,20(3):225-231.
[46] Swisher SG,Hofstetter W,Komaki R,et al. Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer[J].Ann Thorac Surg,2010,90(3):892-898;discussion 898-9.DOI:10.1016/j.athoracsur.2010.04.061.
[47] Burmeister BH,Thomas JM,Burmeister EA,et al. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase Ⅱ trial[J].Eur J Cancer,2011,47(3):354-360.DOI:10.1016/j.ejca.2010.09.009.
[48] Klevebro F,Alexandersson von D beln G,Wang N,et al. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction[J].Ann Oncol,2016,27(4):660-667.DOI:10.1093/annonc/mdw010.
[49] Stahl M,Walz MK,Stuschke M,et al. Phase Ⅲ comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction[J].J Clin Oncol,2009,27(6):851-856.DOI:10.1200/JCO.2008.17.0506.
[50] Stahl M,Walz MK,Riera-Knorrenschild J,et al. Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET):long-term results of a controlled randomised trial[J].Eur J Cancer,2017,81:183-190.DOI:10.1016/j.ejca.2017.04.027.
[51] Fan M,Lin Y,Pan J,et al. Survival after neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for resectable esophageal carcinoma:A meta-analysis[J].Thorac Cancer,2016,7(2):173-181.DOI:10.1111/1759-7714.12299.
[52] Luu TD,Gaur P,Force SD,et al. Neoadjuvant chemoradiation versus chemotherapy for patients undergoing esophagectomy for esophageal cancer[J].Ann Thorac Surg,2008,85(4):1217-1223;discussion 1223-4.DOI:10.1016/j.athoracsur.2007.11.070.
[53] Deng HY, Wang WP, Wang YC, et al. Neoadjuvant chemoradiotherapy or chemotherapy? A comprehensive systematic review and meta-analysisof the options for neoadjuvant therapy for treating oesophageal cancer[J]. Eur J Cardiothorac Surg,2017,51(3):421-431.DOI:10.1093/ejcts/ezw315.
[54] Cao XF,He XT,Ji L,et al. Effects of neoadjuvant radiochemotherapy on pathological staging and prognosis for locally advanced esophageal squamous cell carcinoma[J].Dis Esophagus,2009 22(6):477-481.DOI:10.1111/j.1442-2050.2008.00910.x.
[55] Nakamura K,Kato K,Igaki H,et al. Three-arm phase Ⅲ trial comparing cisplatin plus 5-FU (CF) versus docetaxel,cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109,NExT study)[J].Jpn J Clin Oncol,2013,43(7):752-755.DOI:10.1093/jjco/hyt061.
[56] Tang H,Tan L,Shen Y,et al. CMISG1701:a multicenter prospective randomized phase Ⅲ clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT3-4aN0-1M0)(NCT03001596)[J].BMC Cancer,2017, 28;17(1):450.
[57] Haisley KR,Laird AE,Nabavizadeh N,et al. Association of intervals between neoadjuvant chemoradiation and surgical resection with pathologic complete response and survival in patients with esophageal cancer[J].JAMA Surg,2016,151(11):e162743.DOI:10.1001/jamasurg.2016.2743.
[58] Lee A,Wong AT,Schwartz D,et al. Is There a benefit to prolonging the interval between neoadjuvant chemoradiation and esophagectomy in esophageal cancer[J]? Ann Thorac Surg,2016,102(2):433-438.DOI:10.1016/j.athoracsur.2016.02.058.
[59] Lin G,Han SY,Xu YP,et al. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in esophageal cancer:a meta-analysis of published studies[J].Dis Esophagus,2016,29(8):1107-1114.DOI:10.1111/dote.12432.
[60] Tie H,He F,Shen J,et al. Prolonged interval between neoadjuvant chemoradiotherapy and esophagectomy does not benefit the outcome in esophageal cancer:a systematic review and meta-analysis[J].Dis Esophagus,2018,31(1):1-9.DOI:10.1093/dote/dox116.
[61] Kathiravetpillai N,Ko terM,van der Sangen MJ,et al. Delaying surgery after neoadjuvant chemoradiotherapy does not significantly influence postoperative morbidity or oncological outcome in patients with oesophageal adenocarcinoma[J].Eur J Surg Oncol,2016,42(8):1183-1190.DOI:10.1016/j.ejso.2016.03.033.
[62] Ranney DN,Mulvihill MS,Yerokun BA,et al. Surgical resection after neoadjuvant chemoradiation for oesophageal adenocarcinoma:what is the optimal timing[J]? Eur J Cardiothorac Surg,2017,52(3):543-551.DOI:10.1093/ejcts/ezx132.
[63] Chiu CH,Chao YK,Chang HK,et al. Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma:does delayed surgery impact outcome[J]? Ann Surg Oncol,2013,20(13):4245-4251.DOI:10.1245/s10434-013-3139-7. |